PMID- 30317560
OWN - NLM
STAT- MEDLINE
DCOM- 20200316
LR  - 20200316
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 234
IP  - 4
DP  - 2019 Apr
TI  - Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug 
      resistance.
PG  - 3238-3253
LID - 10.1002/jcp.26768 [doi]
AB  - The cancer stem cell (CSC) model encompasses an advantageous paradigm that in 
      recent decades provides a better elucidation for many important biological 
      aspects of cancer initiation, progression, metastasis, and, more important, 
      development of multidrug resistance (MDR). Such several other hematological 
      malignancies and solid tumors and the identification and isolation of ovarian 
      cancer stem cells (OV-CSCs) show that ovarian cancer also follows this 
      hierarchical model. Gaining a better insight into CSC-mediated resistance holds 
      promise for improving current ovarian cancer therapies and prolonging the 
      survival of recurrent ovarian cancer patients in the future. Therefore, in this 
      review, we will discuss some important mechanisms by which CSCs can escape 
      chemotherapy, and then review the recent and growing body of evidence that 
      supports the contribution of CSCs to MDR in ovarian cancer.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Mihanfar, Aynaz
AU  - Mihanfar A
AD  - Faculty of Medicine, Department of Biochemistry, Urmia University of Medical 
      Sciences, Urmia, Iran.
FAU - Aghazadeh Attari, Javad
AU  - Aghazadeh Attari J
AD  - Department of Neurosurgery, Urmia University of Medical Sciences, Urmia, Iran.
FAU - Mohebbi, Iraj
AU  - Mohebbi I
AD  - Department of Occupational Health, Urmia University of Medical Sciences, Urmia, 
      Iran.
FAU - Majidinia, Maryam
AU  - Majidinia M
AD  - Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran.
FAU - Kaviani, Mojtaba
AU  - Kaviani M
AD  - School of Nutrition and Dietetics, Acadia University, Wolfville, Nova Scotia, 
      Canada.
FAU - Yousefi, Mehdi
AU  - Yousefi M
AD  - Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Yousefi, Bahman
AU  - Yousefi B
AUID- ORCID: 0000-0002-4220-1527
AD  - Molecular Medicine Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181014
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Biomarkers, Tumor/metabolism
MH  - *Drug Resistance, Multiple
MH  - *Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Neoplastic Stem Cells/*drug effects/metabolism/pathology
MH  - Ovarian Neoplasms/*drug therapy/metabolism/pathology
MH  - Signal Transduction
OTO - NOTNLM
OT  - CSC markers
OT  - cancer stem cells
OT  - multidrug resistance
OT  - ovarian cancer
OT  - self-renewal
OT  - tumor-initiating cells
EDAT- 2018/10/15 06:00
MHDA- 2020/03/17 06:00
CRDT- 2018/10/15 06:00
PHST- 2017/10/13 00:00 [received]
PHST- 2018/04/27 00:00 [accepted]
PHST- 2018/10/15 06:00 [pubmed]
PHST- 2020/03/17 06:00 [medline]
PHST- 2018/10/15 06:00 [entrez]
AID - 10.1002/jcp.26768 [doi]
PST - ppublish
SO  - J Cell Physiol. 2019 Apr;234(4):3238-3253. doi: 10.1002/jcp.26768. Epub 2018 Oct 
      14.